Advertisement

AIDS and Behavior

, Volume 23, Issue 1, pp 126–131 | Cite as

The Use of Efavirenz During Pregnancy is Associated with Suicidal Ideation in Postpartum Women in Rural South Africa

  • Deborah L. JonesEmail author
  • Violeta J. Rodriguez
  • Maria L. Alcaide
  • Stephen M. Weiss
  • Karl Peltzer
Original Paper

Abstract

Efavirenz is used for the management of HIV infection during pregnancy in South Africa (SA), but it is contraindicated in patients with history of depression due to possible suicidal ideation. This study compared suicidal ideation 12-months postpartum among women receiving and not receiving efavirenz in rural SA, where high rates of depression have been identified. Antenatal psychological intimate partner violence (IPV; AOR = 1.04), depression (AOR = 1.06) and detection of efavirenz in dried blood spot at 32 weeks predicted suicidal ideation 12-months postnatally (AOR = 2.29), controlling for antenatal stigma and physical IPV. Findings support using alternative agents for the management of HIV during pregnancy.

Keywords

Pregnancy WOMEN Efavirenz Suicidal ideation Postpartum South Africa 

Resumen

Efavirenz es comúnmente utilizado para el tratamiento de la infección por el VIH durante el embarazo en Sudáfrica, pero está contraindicado en pacientes con antecedentes de depresión debido a la posible asociación de su uso con la ideación suicida. Este estudio comparó la ideación suicida a los 12 meses después del parto en mujeres que tomaron o no tomaron Efavirenz durante el embarazo en zonas rurales de Sudáfrica, donde se han identificado altas tasas de depresión. La violencia psicológica prenatal en la pareja (IPV, AOR = 1.04), la depresión (AOR = 1.06) y la detección de Efavirenz en la sangre (medida en muestras de sangre seca) a las 32 semanas predijeron ideación suicida a los 12 meses postparto (AOR = 2.29) en un analysis controlando el estigma prenatal y la IPV física. Los hallazgos respaldan el uso de agentes alternativos para el tratamiento del VIH durante el embarazo.

Notes

Funding

This study was funded by a grant from the National Institutes of Health, R01HD078187, and with the support of the University of Miami Miller School of Medicine Center for AIDS Research, funded by an NIH grant, P30AI073961.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10461_2018_2213_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 17 kb)

References

  1. 1.
    World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2016. http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1.
  2. 2.
    Ford N, Mofenson L, Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2014;28(Suppl 2):S123–31.Google Scholar
  3. 3.
    Raffi F, Pozniak AL, Wainberg MA. Has the time come to abandon efavirenz for first-line antiretroviral therapy? J Antimicrob Chemother. 2014;69(7):1742–7.Google Scholar
  4. 4.
    Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. 2018. https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
  5. 5.
    EACS Treatment Guidelines 9.0: European AIDS Clinical Society. 2017. http://www.eacsociety.org/files/guidelines_9.0-english.pdf.
  6. 6.
    Napoli AA, Wood JJ, Coumbis JJ, Soitkar AM, Seekins DW, Tilson HH. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc. 2014;17(1).Google Scholar
  7. 7.
    Smith C, Ryom L, d’Arminio Monforte A, Reiss P, Mocroft A, El-Sadr W, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D: A: D study. J Int AIDS Soc. 2014;17(4):19214.Google Scholar
  8. 8.
    Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Gonzalez-Garcia M, Molto J, Negredo E, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009;11(2):103–9.Google Scholar
  9. 9.
    Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161(1):1–10.Google Scholar
  10. 10.
    Bengtson AM, Pence BW, Mollan KR, Edwards JK, Moore RD, O’cleirigh C, et al. The relationship between efavirenz as initial antiretroviral therapy and suicidal thoughts among HIV-infected adults in routine care. j Acquir Immune Defic Syndr. 2017;76(4):402–8.Google Scholar
  11. 11.
    Arenas-Pinto A, Grund B, Sharma S, Martinez E, Cummins N, Fox J, et al. Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial. Clin Infect Dis. 2018.  https://doi.org/10.1093/cid/ciy051.Google Scholar
  12. 12.
    Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014;14(7):590–9.Google Scholar
  13. 13.
    Sowa NA, Cholera R, Pence BW, Gaynes BN. Perinatal depression in HIV-infected African women: a systematic review. J Clin Psychiatry. 2015;76(10):1385–96.Google Scholar
  14. 14.
    Stringer EM, Meltzer-Brody S, Kasaro M, Stuebe AM, Wiegand S, Paul R, et al. Depression, pregnancy, and HIV: the case to strengthen mental health services for pregnant and post-partum women in sub-Saharan Africa. Lancet Psychiatry. 2014;1(2):159–62.Google Scholar
  15. 15.
    Peltzer K, Rodriguez VJ, Jones D. Prevalence of prenatal depression and associated factors among HIV-positive women in primary care in Mpumalanga province, South Africa, Sahara. J J Soc Asp H. 2016;13(1):60–7.Google Scholar
  16. 16.
    Rodriguez VJ, Cook R, Peltzer K, Jones DL. Prevalence and psychosocial correlates of suicidal ideation among pregnant women living with HIV in Mpumalanga Province, South Africa. AIDS care. 2017;29(5):593–7.Google Scholar
  17. 17.
    Vitoria M, Ford N, Clayden P, Pozniak AL, Hill AM. When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank. Curr Opin HIV AIDS. 2017;12(4):414–22.Google Scholar
  18. 18.
    Stein A, Pearson RM, Goodman SH, Rapa E, Rahman A, McCallum M, et al. Effects of perinatal mental disorders on the fetus and child. Lancet. 2014;384(9956):1800–19.Google Scholar
  19. 19.
    Gelaye B, Rondon MB, Araya R, Williams MA. Epidemiology of maternal depression, risk factors, and child outcomes in low-income and middle-income countries. Lancet Psychiatry. 2016;3(10):973–82.Google Scholar
  20. 20.
    Rodriguez VJ, Matseke G, Cook R, Bellinger S, Weiss SM, Alcaide ML, et al. Infant development and pre-and post-partum depression in rural South African HIV-infected women. AIDS Behav. 2017;22:1–9.Google Scholar
  21. 21.
    Gaida R, Truter I, Grobler C. Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naive patients in public-sector clinics in the Eastern Cape. S Afr J Hiv Med. 2016;17(1):1–6.Google Scholar
  22. 22.
    Jones DL, Peltzer K, Weiss SM, Sifunda S, Dwane N, Ramlagan S, et al. Implementing comprehensive prevention of mother-to-child transmission and HIV prevention for South African couples: study protocol for a randomized controlled trial. Trials. 2014;15:417.Google Scholar
  23. 23.
    Department of Health—Republic of South Africa. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. 2014.Google Scholar
  24. 24.
    Department of Health—Republic of South Africa. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. 2013.Google Scholar
  25. 25.
    Straus M. Measuring intrafamily conflict and violence: The conflict tactics (CT) scales. J Marriage Fam. 1979;41:75–88.Google Scholar
  26. 26.
    Ellsberg M, Jansen HA, Heise L, Watts CH, Garcia-Moreno C, Health WHOM-cSoWs, et al. Intimate partner violence and women’s physical and mental health in the WHO multi-country study on women’s health and domestic violence: an observational study. Lancet. 2008;371(9619):1165–72.Google Scholar
  27. 27.
    Kalichman SC, Simbayi LC, Cloete A, Mthembu PP, Mkhonta RN, Ginindza T. Measuring AIDS stigmas in people living with HIV/AIDS: the Internalized AIDS-Related Stigma Scale. AIDS Care. 2009;21(1):87–93.Google Scholar
  28. 28.
    Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, et al. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. J Acquir Immune Defic Syndr. 2013;62(3):275–81.Google Scholar
  29. 29.
    Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item edinburgh postnatal depression scale. Br J Psychiatry. 1987;150:782–6.Google Scholar
  30. 30.
    Rochat TJ, Bland RM, Tomlinson M, Stein A. Suicide ideation, depression and HIV among pregnant women in rural South Africa. Health. 2013;5(3A):650–61.Google Scholar
  31. 31.
    Howard LM, Flach C, Mehay A, Sharp D, Tylee A. The prevalence of suicidal ideation identified by the Edinburgh Postnatal Depression Scale in postpartum women in primary care: findings from the RESPOND trial. BMC Pregnancy Childbirth. 2011;11:57.Google Scholar
  32. 32.
    Gausia K, Fisher C, Ali M, Oosthuizen J. Antenatal depression and suicidal ideation among rural Bangladeshi women: a community-based study. Arch Womens Ment Health. 2009;12(5):351–8.Google Scholar
  33. 33.
    Alcaide ML, Ramlagan S, Rodriguez VJ, Cook R, Peltzer K, Weiss SM, et al. Self-report and dry blood spot measurement of antiretroviral medications as markers of adherence in pregnant women in rural South Africa. AIDS Behav. 2017;21(7):2135–40.Google Scholar
  34. 34.
    World Health Organization Statement on Doultegravir. May 18th, 2018. http://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf?ua=1.
  35. 35.
    Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV. Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother. 2015;70(10):2693–708.Google Scholar
  36. 36.
    Cooper PJ, Tomlinson M, Swartz L, Landman M, Molteno C, Stein A, et al. Improving quality of mother-infant relationship and infant attachment in socioeconomically deprived community in South Africa: randomised controlled trial. BMJ. 2009;338:b974.Google Scholar
  37. 37.
    Petersen I, Bhana A, Baillie K, Consortium MRP. The feasibility of adapted group-based interpersonal therapy (IPT) for the treatment of depression by community health workers within the context of task shifting in South Africa. Community Ment Health J. 2012;48(3):336–41.Google Scholar
  38. 38.
    Bengtson AM, Pence BW, Mollan KR, Edwards JK, Moore RD, O’cleirigh C, et al. the relationship between efavirenz as initial antiretroviral therapy and suicidal thoughts among HIV-infected adults in routine care. JAIDS J Acquir Immune Defic Syndr. 2017;76(4):402–8.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioral SciencesUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Department of PsychologyUniversity of GeorgiaAthensUSA
  3. 3.Ford Foundation Fellow, National Academies of Sciences, Engineering, and MedicineWashingtonUSA
  4. 4.Division of Infectious Diseases, Department of MedicineUniversity of Miami Miller School of MedicineMiamiUSA
  5. 5.HIV/AIDS/STIs and TB (HAST) Research ProgrammeHuman Sciences Research CouncilPretoriaSouth Africa
  6. 6.Department of Research & InnovationUniversity of LimpopoSovengaSouth Africa

Personalised recommendations